Fritextsökning
Artiklar per år
Innehållstyper
-
The Swedish innovation model: “There is a paradox”
It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?
-
Setback for Moderna in patent dispute with mRNA competitors
Moderna has suffered a setback in a patent battle against their worst competitors in covid vaccines, Biontech and its partner Pfizer.
-
Eli Lilly to build a USD 2.5-billion plant in Germany
US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.
-
Novo Nordisk to invest billions in Danish manufacturing facilities
Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Kalundborg, Denmark.
-
The Swedish Academy of Sciences: “We have too many researchers”
Sweden does not need more researchers, but it does need better ones. According to the Royal Swedish Academy of Sciences, funding should be distributed to favour excellence.
-
High biological age is linked to a higher risk of dementia and stroke
It is a well-known fact that people age at different rates, and a recent study at the Karolinska Institute suggests that people with a biological age higher than their actual age are significantly more likely to suffer from dementia and stroke.
-
Tirzepatide approved for obesity by the FDA – to be branded as Zepbound
Diabetes drug tirzepatide has now also been approved in the US for treating obesity.
-
Svensk vaccinutvecklare får 24 miljoner av brittiskt forskningsprogram
Abera Bioscience får upp till motsvarande cirka 24 miljoner kronor i finansiering från ett brittiskt program inriktat på vacciner som ska stoppa epidemier i låg- och medelinkomstländer.
-
Hög biologisk ålder kopplas till ökad risk för demens och stroke
Människor åldras i olika takt, som bekant. Nu indikerar en studie vid Karolinska institutet att personer med högre biologisk ålder än deras faktiska ålder löper signifikant större risk att drabbas av åkommor som demens och blodpropp i hjärnan.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic have achieved just that, and they are thus making a significant contribution to the history
-
“A major energy boost for the entire cancer vaccine field”
The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment line for cancer patients, and the company recently presented positive data from a phase II study.
-
High-tech companies are increasingly focusing on health
Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more about them advancing their positions,” says Anna Lefevre Skjöldebrand, CEO of Swedish Medtech.
-
Study: Cancer vaccine prolongs survival in difficult-to-treat tumour disease
According to a new study, a combination of a cancer vaccine from Norwegian company Ultimovacs and two immunotherapies significantly prolonged survival in cases of the aggressive cancer mesothelioma.
-
“You discover one thing – and then 10 new questions arise”
COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current focus is on her next field: the role of gut flora in human health.
-
Novo Nordisk buys drug candidate in billion dollar deal
The Danish pharmaceutical giant Novo Nordisk have made an agreement with KBP Biosciences to aqcuire the hypertension drug ocedurenone for up to 1.3 billion dollars, which corresponds to approximately 14 billion Swedish kronor.
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite book. Perhaps her interest in science was born there and then, as science and new technology have since been a constant feature of her working life. Today, she is a Healthcare Manager in Microsoft’s Western Europe team.
-
Study names with an attitude – more important than you might think
Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.
-
Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”
The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the right patients be found in time, and will the healthcare system’s resources be sufficient? Life Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.
-
Marie Gårdmark: ”The situation is not satisfactory”
”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients?” writes Marie Gårdmark in a column.
-
Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”
With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve been in the thick of things and part of the development for so long now, but I’m also looking forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden
-
Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”
It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless different assignments later, Per Alfredsson, born and raised in Södertälje, is CEO of Astra Zeneca Sweden, which employs 7800 people in Södertälje, Stockholm and Gothenburg. “It was a very special feeling to be in charge of the entire organisation,” he says in an interview about his career and potential future blockbusters.
-
Studienamn med attityd – viktigare än man kan tro
Ironman, T-rex, Star-trec. Popcorn, Proper, Scout. Nej, det handlar varken om fantasyfilmer eller hundnamn. Utan om benämningar på pågående cancerstudier i Sverige.
-
Linköpingsforskare utvecklar ny klass av antibiotika
Forskare vid Linköpings universitet hoppas i framtiden kunna använda en grupp av läkemedel som ofta används vid behandling av cancer för att bekämpa bakterieinfektioner. De har utvecklat en metod som ska leverera läkemedlet och ta död på bakterien på plats.